<p>Eledon Pharmaceuticals, Inc.（纳斯达克代码：ELDN - 获取免费报告）周一的股价下跌了 3.4%。该公司的股价最低曾达到$3.96，最后交易价为$4.01。在午盘交易中，约有 395,521 股成交，较平均每日成交量 265,548 股增加了 49%。该股票此前收盘价为$4.15。</p>
<p>获取 <strong>Eledon Pharmaceuticals</strong> 的提醒：</p>
<h2>分析师设定新目标价</h2>
<p>ELDN 已成为多份研究报告的主题。HC Wainwright 在 11 月 20 日的报告中重申了对 Eledon Pharmaceuticals 的 “买入” 评级，并设定了$16.00 的目标价。Guggenheim 在 1 月 28 日的报告中开始覆盖 Eledon Pharmaceuticals 的股票。他们为该公司设定了 “买入” 评级和$9.00 的目标价。</p>
<p><strong>查看我们关于 ELDN 的最新研究报告</strong></p>
<h2>Eledon Pharmaceuticals 的价格表现</h2>
<p>该公司的市值为 2.3955 亿美元，市盈率为-2.00，贝塔值为 0.79。该公司的 50 日移动平均价格为$4.35，200 日移动平均价格为$3.79。</p>
<h2>对 Eledon Pharmaceuticals 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近修改了对该公司的持股。RA Capital Management L.P.在第四季度收购了 Eledon Pharmaceuticals 的新股份，价值约为$14,693,000。First Light Asset Management LLC 在第四季度收购了 Eledon Pharmaceuticals 的新股份，价值约为$9,595,000。Blue Owl Capital Holdings LP 在第四季度收购了 Eledon Pharmaceuticals 的新股份，价值约为$8,075,000。Sphera Funds Management LTD.在第四季度将其在 Eledon Pharmaceuticals 的持股增加了 96.7%。Sphera Funds Management LTD.现在拥有该公司 2,551,619 股股票，价值$10,513,000，在此期间又购买了 1,254,298 股。最后，Frazier Life Sciences Management L.P.在第四季度收购了 Eledon Pharmaceuticals 的新股份，价值约为$4,848,000。机构投资者和对冲基金持有该公司 56.77% 的股票。</p>
<h2>关于 Eledon Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Eledon Pharmaceuticals, Inc 是一家临床阶段的生物技术公司。该公司利用其免疫学专业知识，针对 CD40 配体（CD40L，也称为 CD154）通路开发疗法，以保护移植器官并防止排斥，以及治疗肌萎缩侧索硬化症（ALS）。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Eledon Pharmaceuticals</li>
<li>市值计算器：如何计算市值</li>
<li>看跌投资者可以在抗衰退 ETF 中寻求避难所</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>3 只超卖的七只奇迹股票在关键水平：现在买入？</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>3M 将在年中达到$175，并且更高的高点是可能的</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Eledon Pharmaceuticals 吗？</h2>
<p>在考虑 Eledon Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Eledon Pharmaceuticals 并不在名单上。</p>
<p>虽然 Eledon Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ELDN

<p>Eledon Pharmaceuticals（纳斯达克代码：ELDN）股价在交易中下跌 3.4%，至 4.01 美元，成交量较平均水平增加 49%。分析师们设定了价格目标，HC Wainwright 维持 “买入” 评级，目标价为 16.00 美元，而 Guggenheim 则设定了 9.00 美元的目标。机构投资者持有该股票的 56.77%。Eledon 专注于免疫学，开发器官移植保护和 ALS 治疗的疗法</p>

<p>Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report)'s share price dropped 3.4% during trading on Monday . The company traded as low as $3.96 and last traded at $4.01. Approximately 395,521 shares traded hands during mid-day trading, an increase of 49% from the average daily volume of 265,548 shares. The stock had previously closed at $4.15.</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals, Inc.（纳斯达克代码：ELDN - 获取免费报告）周一的股价下跌了 3.4%。该公司的股价最低曾达到$3.96，最后交易价为$4.01。在午盘交易中，约有 395,521 股成交，较平均每日成交量 265,548 股增加了 49%。该股票此前收盘价为$4.15。</p>
</div><p>Get <strong>Eledon Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Eledon Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>ELDN has been the subject of a number of research reports. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $16.00 price objective on shares of Eledon Pharmaceuticals in a report on Wednesday, November 20th. Guggenheim started coverage on shares of Eledon Pharmaceuticals in a report on Tuesday, January 28th. They set a &#34;buy&#34; rating and a $9.00 price target for the company.</p>
<div class="lb-trans"><p>ELDN 已成为多份研究报告的主题。HC Wainwright 在 11 月 20 日的报告中重申了对 Eledon Pharmaceuticals 的 “买入” 评级，并设定了$16.00 的目标价。Guggenheim 在 1 月 28 日的报告中开始覆盖 Eledon Pharmaceuticals 的股票。他们为该公司设定了 “买入” 评级和$9.00 的目标价。</p>
</div><p><strong>Check Out Our Latest Research Report on ELDN</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ELDN 的最新研究报告</strong></p>
</div><h2>Eledon Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Eledon Pharmaceuticals 的价格表现</h2>
</div><p>The company has a market cap of $239.55 million, a price-to-earnings ratio of -2.00 and a beta of 0.79. The firm's fifty day moving average price is $4.35 and its 200-day moving average price is $3.79.</p>
<div class="lb-trans"><p>该公司的市值为 2.3955 亿美元，市盈率为-2.00，贝塔值为 0.79。该公司的 50 日移动平均价格为$4.35，200 日移动平均价格为$3.79。</p>
</div><h2>Hedge Funds Weigh In On Eledon Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Eledon Pharmaceuticals 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of the company. RA Capital Management L.P. acquired a new stake in Eledon Pharmaceuticals in the fourth quarter worth about $14,693,000. First Light Asset Management LLC acquired a new stake in Eledon Pharmaceuticals in the fourth quarter worth about $9,595,000. Blue Owl Capital Holdings LP acquired a new stake in Eledon Pharmaceuticals in the fourth quarter worth about $8,075,000. Sphera Funds Management LTD. lifted its holdings in Eledon Pharmaceuticals by 96.7% in the fourth quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company's stock worth $10,513,000 after purchasing an additional 1,254,298 shares during the period. Finally, Frazier Life Sciences Management L.P. acquired a new stake in Eledon Pharmaceuticals in the fourth quarter worth about $4,848,000. Institutional investors and hedge funds own 56.77% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近修改了对该公司的持股。RA Capital Management L.P.在第四季度收购了 Eledon Pharmaceuticals 的新股份，价值约为$14,693,000。First Light Asset Management LLC 在第四季度收购了 Eledon Pharmaceuticals 的新股份，价值约为$9,595,000。Blue Owl Capital Holdings LP 在第四季度收购了 Eledon Pharmaceuticals 的新股份，价值约为$8,075,000。Sphera Funds Management LTD.在第四季度将其在 Eledon Pharmaceuticals 的持股增加了 96.7%。Sphera Funds Management LTD.现在拥有该公司 2,551,619 股股票，价值$10,513,000，在此期间又购买了 1,254,298 股。最后，Frazier Life Sciences Management L.P.在第四季度收购了 Eledon Pharmaceuticals 的新股份，价值约为$4,848,000。机构投资者和对冲基金持有该公司 56.77% 的股票。</p>
</div><h2>About Eledon Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Eledon Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).</p>
<div class="lb-trans"><p>Eledon Pharmaceuticals, Inc 是一家临床阶段的生物技术公司。该公司利用其免疫学专业知识，针对 CD40 配体（CD40L，也称为 CD154）通路开发疗法，以保护移植器官并防止排斥，以及治疗肌萎缩侧索硬化症（ALS）。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Eledon Pharmaceuticals</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Bearish Investors Can Seek Refuge in Recession-Resistant ETFs</li>
<li>How to Calculate Retirement Income: MarketBeat’s Calculator</li>
<li>3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?</li>
<li>Airline Stocks - Top Airline Stocks to Buy Now</li>
<li>3M to Hit $175 by Mid-Year, and Higher Highs Are Likely</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Eledon Pharmaceuticals</li>
<li>市值计算器：如何计算市值</li>
<li>看跌投资者可以在抗衰退 ETF 中寻求避难所</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>3 只超卖的七只奇迹股票在关键水平：现在买入？</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>3M 将在年中达到$175，并且更高的高点是可能的</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eledon Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Eledon Pharmaceuticals 吗？</h2>
</div><p>Before you consider Eledon Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Eledon Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Eledon Pharmaceuticals 并不在名单上。</p>
</div><p>While Eledon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Eledon Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Eledon Pharmaceuticals（纳斯达克股票代码：ELDN）股价下跌 3.4% - 以下是原因